anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A Kalopanax pictus(Thunb.) Nakai extract containing Kalopanax saponin A as an active ingredient is provided. The saponin has an inhibition effect on carcinoma and is thus useful as an anticarcinogenic agent. The composition containing the saponin is applied to foods, beverages, medicines, tea products and other health supplementary foods. CONSTITUTION: Kalopanax saponin A is obtained by extracting Kalopanax pictus(Thunb.) Nakai, suspending an extract in distilled water, fractioning the suspended extract four times with a solvent, and vacuum-drying and purifying fractions by chromatography. The anticarcinogenic effect of Kalopanax saponin A on bromobenzene is analyzed. As a result of the analysis, the bromobenzene treated group increases hepatic microsomal aminopyrine N-dimethylase which is a kind of cytochrome P-450 enzymes and dramatically decreases epoxy hydrolase. However, the Kalopanax saponin A treated group inhibits the activity of bromobenzene.
The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment whose sequence corresponds to a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid sequence of the peptide fragment corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention further relates to DNA sequences corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; wherein the DNA sequences are able to express specific proteins in an  E. Coli  expression system.
Our previous in vitro studies showed that excitotoxicity evoked by glutamate analogue kainate (KA) significantly decreased the number of rat spinal neurons and triggered high release of glutamate leading to locomotor network block. Our current objective was to assess the role of CREB as a predictive marker of damage following chemically-induced spinal cord injury by using in vivo and in vitro models. Thus, in vivo excitotoxicity in Balb/c adult mice was induced by KA intraspinal injection, while in vitro spinal cord excitotoxicity was produced by bath-applied KA. KA application evoked significant neuronal loss, deterioration in hindlimb motor coordination and thermal allodynia. In addition, immunohistochemical analysis showed that KA application resulted in decreased number of CREB positive nuclei in the ventral horn and in dorsal layers III-IV. Our data suggests that excitotoxic-induced neuronal loss may be potentially predicted by altered CREB nuclear translocation.
A method for facilitating delivery of a phosphatidylinositol polyphosphate or derivative thereof into a eukaryotic cell is disclosed. The method includes forming a complex of the phosphatidylinositol polyphosphate or derivative with a polyamine, and then contacting the cell with the complex. Preferred polyamines include aminoglycosides, dendrimeric polyamines, and histones. Compositions of matter for use in the method are also described. A method for screening compounds for minimum toxicity to eukaryotic cells and maximum toxicity to bacterial cells is also disclosed. Also disclosed is a method for monitoring calcium flux in a cell.
Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then activated, genetically modified, and propagated, preferably, in separate or isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, preferably promoting or inducing the retention of cell surface receptors, such as CD62L, CD28, and/or CD27. Included herein are also methods of treatment, inhibition, amelioration, or elimination of a cancer by administering to a subject in need thereof, one or more types of the genetically engineered T-cells or compositions that comprise the genetically engineered T-cell prepared as described herein. (FIG. 11A & FIG. 11B)
PURPOSE: To enable a stent to hold a medicine of an amount to be imporant necessary for a medical treatment by evaporating a solvent after applying the solvent and a polymer dissolved in the solvent and a solution containing a substance for the medical treatment dispersed in the solvent respectively to a cylindrical stent body. CONSTITUTION: In the case that an intravascular stent is produced, first, a cylindrical stent body is generally formed. Next, a solvent, a polymer dissolved in the solvent, and a solution containing a substance necessary for a medical treatment dispersed in the solvent are applied to the stent body. Successively, the solvent is evaporated. A metallic surface or a polymeric surface is arranged in the stent body. On the other hand, the solution is applied by atomizing and dipping or plural times of these application steps and drying. The ratio of the medicine to the dissolved polymer in the solution is changed by plural times of the application step. Furthermore, the polymer has bioabsorbability. By doing so, a medicine can be held to the stent of only its important amount necessary for a medical treatment.
Pneumonia is the leading cause of death from hospital-acquired infections. Intubation and mechanical ventilation greatly increase the risk of bacterial ventilator associated pneumonia. Growth of potentially pathogenic bacteria in dental plaque of critically ill patients provides a nidus of infection for microorganisms that have been shown to be responsible for the development of Ventilator Associated Pneumonia. Since these organisms are concentrated in dental plaque, removal of organisms from the oral cavity by oral care interventions is a theoretically attractive method to reduce the risk of development of Ventilator Associated Pneumonia. However, evidence-based protocols for oral care of mechanically ventilated patients are not available. Results of the study have the potential to improve nursing care, and to positively affect patient well-being, morbidity, mortality, and health care costs.
OHTUVAYRE (ensifentrine) 3 mg/2.5 mL inhalation suspension is a sterile aqueous suspension in a unit-dose low-density polyethylene ampule. OHTUVAYRE is supplied in a carton of 60 unit-dose ampules (NDC 83034-003-60). Each ampule is overwrapped in a sealed foil pouch. The ampule containing OHTUVAYRE should be shaken vigorously to ensure complete resuspension of the active ingredient immediately prior to use. The used ampule and any residual content should be discarded after use.

Store OHTUVAYRE in the protective foil pouch (only remove from foil pouch immediately before use) at controlled room temperature (68°F to 77°F [20°C to 25°C], excursions permitted from 59ºF to 86ºF [15ºC to 30ºC]) [See USP Controlled Room Temperature], maintaining the orientation indicated on the carton. Protect from direct sunlight and excessive heat. Do not freeze.
PROBLEM TO BE SOLVED: To obtain a composition, capable of improving effects essentially possessed by an active oxygen scavenger and effectively suppressing the production of peroxylipids and extremely useful for the beauty culture and medicine by using the active oxygen scavenger with a specific extract in combination. SOLUTION: This composition is obtained by formulating an active oxygen scavenger with a lignan glycoside in combination. A sesaminol glycoside represented by formula I [R1 and R2 are each glycosyl composed of one to four saccharides, which are one or more selected from glucose, galactose and fructose; (a) to (c) are each 0 or 1], especially a compound represented by formula II (Glc is the glycosyl) or formula III or IV is preferred. The amount of the formulated sesaminol glycoside is 0.001-5 wt.% in the case of using, e.g. the compound represented by formula 1 to IV. A superoxide dismutase, mannitol, hydroquinone, etc., are preferred as the active oxygen scavenger. The amount thereof formulated is 0.0001-5 wt.%.
AIM: Acquired post-transplant diaphragmatic hernia (PTDH) is a rare complication of liver transplantation (LT) in children. We aimed to present our experience in PTDH, and a possible causative background is discussed.
METHODS: Medical records of patients who had undergone diaphragmatic repair following LT between 2015 and 2023 were reviewed. Demographic information, details of primary diseases necessitating LT, transplantation techniques, and clinical findings associated with PTDH were evaluated.
RESULTS: There were seven patients with PTDH. Median age at transplantation was 69 (range: 9-200) months. Five patients received a left lateral sector, one patient had a right lobe, and one had a left lobe graft. Time between LT and PTDH was 9 (2-123) months. One patient who was diagnosed in the postoperative 10th year was asymptomatic. Respiratory distress and abdominal pain were the main symptoms among all. All patients underwent laparotomy, and primary repair was performed in six patients, and one patient required mesh repair because of a large defect. Small intestine herniated in most cases. There were two complicated cases with perforation of the stomach and colonic volvulus. There is no recurrence or long-term complications for the median 60 (20-119) month follow-up period.
CONCLUSION: PTDH is a rare but serious complication. Majority of symptomatic cases present within the first postoperative year, whereas some late-presenting cases may not be symptomatic. Inadvertent injury to the inferior phrenic vasculatures due to excessive use of cauterization for control of hemostasis may be a plausible explanation in those cases.
All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
BACKGROUND: New methods to identify patients who benefit from a primary prophylactic implantable cardioverter-defibrillator (ICD) are needed. T-wave alternans (TWA) has been shown to associate with arrhythmogenesis of the heart and sudden cardiac death. We hypothesized that TWA might be associated with benefit from ICD implantation in primary prevention.
METHODS AND RESULTS: In the EU-CERT-ICD (European Comparative Effectiveness Research to Assess the Use of Primary Prophylactic Implantable Cardioverter-Defibrillators) study, we prospectively enrolled 2327 candidates for primary prophylactic ICD. A 24-hour Holter monitor reading was taken from all recruited patients at enrollment. TWA was assessed from Holter monitoring using the modified moving average method. Study outcomes were all-cause death, appropriate shock, and survival benefit. TWA was assessed both as a contiguous variable and as a dichotomized variable with cutoff points <47 μV and <60 μV. The final cohort included 1734 valid T-wave alternans samples, 1211 patients with ICD, and 523 control patients with conservative treatment, with a mean follow-up time of 2.3 years. TWA ≥60 μV was a predicter for a higher all-cause death in patients with an ICD on the basis of a univariate Cox regression model (hazard ratio, 1.484 [95% CI, 1.024-2.151]; P=0.0374; concordance statistic, 0.51). In multivariable models, TWA was not prognostic of death or appropriate shocks in patients with an ICD. In addition, TWA was not prognostic of death in control patients. In a propensity score-adjusted Cox regression model, TWA was not a predictor of ICD benefit.
CONCLUSIONS: T-wave alternans is poorly prognostic in patients with a primary prophylactic ICD. Although it may be prognostic of life-threatening arrhythmias and sudden cardiac death in several patient populations, it does not seem to be useful in assessing benefit from ICD therapy in primary prevention among patients with an ejection fraction of ≤35%.
Under a changing climate, keeping the food supply steady for an ever-increasing population will require crop plants adapted to environmental fluctuations. Genetic engineering and genome-editing approaches have been used for developing climate-resilient crops. However, genetically modified crops have yet to be widely accepted, especially for small-scale farmers in low-income countries and some societies. Nano-priming (seed exposure to nanoparticles, NPs) has appeared as an alternative to the abovementioned techniques. This technique improves seed germination speed, promotes seedlings' vigor, and enhances plant tolerance to adverse conditions such as drought, salinity, temperature, and flooding, which may occur under extreme weather conditions. Moreover, nano-enabled seed treatment can increase the disease resistance of crops by boosting immunity, which will reduce the use of pesticides. This unsophisticated, farmer-available, cost-effective, and environment-friendly seed treatment approach may help crop plants fight climate change challenges. This review discusses the previous information about nano-enabled seed treatment for enhancing plant tolerance to abiotic stresses and increasing disease resistance. Current knowledge about the mechanisms underlying nanomaterial-seed interactions is discussed. To conclude, the review includes research questions to address before this technique reaches its full potential.
Emergency department (ED) physicians play an important role in the management of pediatric asthma through acute intervention, family education, and appropriate referral to outpatient resources. However, time constraints in the ED limit physicians' ability to appropriately stratify both asthma severity and outpatient referrals. The Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED) improves ED providers assessment of asthma control and disease burden. We hypothesize that implementation of the PACCI-ED at the point of care may help to facilitate appropriate referrals to outpatient asthma care.

ED providers will be randomized to the control or intervention group. Providers in the intervention group will receive the results of the parent-completed PACCI-ED accompanied by a one page summary of referral recommendations aligned with asthma guidelines and based upon asthma severity. Providers in the control group will not receive this information and will provide 'usual care'. All providers will complete a brief demographic questionnaire. School-aged children with a history of asthma presenting to the ED for an asthma exacerbation and discharged home who consent to participate will be assigned to the control or the intervention group based upon the ED provider caring for the patient during their ED encounter. Parents will complete a brief demographic questionnaire, the PACCI-ED, and answer two short qualitative audio-recorded questions about barriers to asthma care during their ED visit. Following the ED visit, additional data will be abstracted from the electronic medical record including outpatient referrals placed at the time of ED discharge and follow-up with the referrals within a one-month time-frame.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention describes new derivatives of BICYCLED amides of the general formula (I)   where R 1 ,R 2 ,R 3 ,R 4  are taken (each) among hydrogen and fluorine atom and at least one and not more two of their mean fluorine atom; R 5  is taken among hydrogen atom and C 1 -C 4 -alkyl; R 6  is taken among hydrogen atom, C 1 -C 4 -alkyl and hydroxy-group or R 5  and R 6  in common with ring carbon form the carbonyl group; R 7  is taken among hydrogen atom and hydroxy-group; R 8  and R 9  are taken (each) among hydrogen atom, C 1 -C 4 -alkyl and cyclo-(C 3  or C 4 )-alkyl or in common with nitrogen atom form morpholino-group, their salts and solvates. Invention describes also pharmaceutical compositions based on compounds of the formula (I) that are used in medicine, in part, as muscle relaxants. Invention describes also a method of treatment of patients with pathological and inflammatory states. Compounds of the formula (I) shows decreased ability to induce sedative effect and coordination disorder as compared with the known agents. EFFECT: enhanced effectiveness of compounds as curative agents. 31 cl, 86 ex
The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.
Being overweight and obese is associated with an elevated risk of developing noncommunicable diseases, which are the leading causes of mortality worldwide. It is a warning that global prevalence of overweight among university students ranges from 20 to 40%, which presents a significant public health problem. To date, there was no research conducted on medical students regarding the prevalence and associated factors of overweight and obesity in the countries of the Western Balkans (Slovenia, Croatia, Bosnia and Herzegovina, North Macedonia, and Serbia). The aim of this study was to determine the prevalence and potential demographic, socioeconomic, and health-related behavioral factors associated with overweight and obesity of medical students from Western Balkans. A cross-sectional study was conducted, surveying 2452 students from 14 medical faculties from 5 countries in the region. The prevalence of overweight was 12% and obesity was 2.3% among medical students from Western Balkans. Male gender and smoking status are significant positive predictors of overweight and obesity. Daily level of physical activity up to 1 h per day, going to preventive check-ups once a year or as a part of annual dormitory check-ups are associated with lower odds of being overweight and obese. By creating adequate public health educational programs, students can be influenced to acquire proper health-related lifestyle habits, which would lead to reducing the prevalence of overweight and obesity among the student population, as well as risk of developing noncommunicable diseases and improving the overall health of the population.
Technologies for providing assistance to a surgeon during a surgical procedure are disclosed. An example method includes identifying a medical condition of a patient and recommending surgical procedures for treatment. An optimal surgical procedure is then determined based on correlations between the medical condition of the patient and outcomes of previous surgical procedures for other patients previously suffering from the medical condition. A 3D model of the patient may be created using current images of an affected area of the patient. Successively, a surgeon is trained using a Virtual Reality simulation. During the training, the surgeon may be allowed to provide annotations. Further, the recommended surgical procedures are based on medical data of the patient, including medical images. Surgical paths are retrieved for addressing the surgical need of the patient, and the surgical paths may be overlaid on image segments, for display for the surgeon. A surgical path is selected from the surgical paths, a surgical step belonging to the surgical path is selected, and an image segment selected from the image segments, based on the surgeon's inputs is used to create the surgical plan.
The invention pertains to the food producing technology. According to the scientific research achievements of cancer-proof, anti-older and disease-preventing nutriology, nutrient species and addition amount for super-nutrient bread with the cancer-proof, anti-older and disease-preventing functions are put forward. The main points of the technical proposal: (1) the using varieties and the addition amount of various cancer-proof nutrients are researched according to the achievements of the cancer-proof nutriology. (2) The using varieties and the addition amount of various anti-older nutrients are researched according to the achievements of the anti-older nutriology. (3) The using varieties and the addition amount of various disease-preventing nutrients are researched according to the achievements of the disease-preventing nutriology. The product is applied to the food of Chinese for improving Chinese physical health level, has the functions of being cancer-proof, anti-older, and disease-preventing, etc. and is good for improving intelligence and physical strength; therefore, the product can improve Chinese health to a new level.
Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. Testosterone gel 1% is not known to cause these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue testosterone gel 1% while the cause is evaluated.
BACKGROUND: Despite several clinical trials, the use of corticosteroid therapy for treating immunoglobulin A nephropathy (IgAN) remains controversial. We aimed to describe the use of corticosteroid therapy combined with supportive therapy in Norwegian patients with IgAN who had progressed to end-stage kidney disease.
METHODS: We conducted a retrospective cohort study using data from the Norwegian Renal Registry. Overall, 143 patients with primary IgAN who progressed to end-stage kidney disease were divided into two groups: the corticosteroid group, who had been treated with corticosteroids and supportive therapy, and the non-corticosteroid group, which had underwent only supportive therapy. The kidney function, time to end-stage kidney disease, and adverse effects were described. The observation period lasted from the diagnostic kidney biopsy until the initiation of kidney replacement therapy.
RESULTS: Of the 143 included patients, 103 underwent supportive therapy alone, and 40 were treated with corticosteroids. Most patients (94%) were treated with renin-angiotensin-system blockade, and all patients reached end-stage kidney disease after a median of 5 years (interquartile range; 2-9 years). Time from diagnosis until end-stage kidney disease was similar in the two study groups (p = 0.98). During 6 months of corticosteroid therapy, median eGFR declined from 21 (interquartile range; 13-46) mL/min/1.73 m2 to 20 (interquartile range; 12-40) mL/min/1.73 m2, and median proteinuria decreased from 5.5 g/24 h to 3.0 g/24 h. Most patients (87.5%) treated with corticosteroids reported adverse events. In our linear regression analysis investigating the time to ESKD, we found that age (β = -0.079, p = 0.008) and proteinuria at diagnosis (β = -0.50, p = 0.01) exhibited statistically significant associations with a delay in the progression to ESKD.
CONCLUSIONS: In this cohort of Norwegian patients with IgAN, corticosteroid therapy did not affect the time from diagnosis until end-stage kidney disease among a cohort of patients who all reached end-stage kidney disease. The treatment was also associated with adverse effects.